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Heterologous protein production in CHO cells imposes a burden on the host cell metabolism and impact cellular physiology on a 
global scale. In this work, a multi-omics approach was applied to characterize the physiological impact of erythropoietin production 
and discover production bottlenecks in a panel of CHO-K1 cells in batch and chemostat culture.
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Common protein expression bottlenecksCell lines
The full metabolic network reconstruction is available here
•  Generate a panel of EPO producing clones   
 with broad specic protein productivity.
• Identify the production bottleneck in the   
 secretory protein production pathway.
• Characterize the burden of EPO production  
 on the host cell metabolism and identify   
 bottlenecks in energy metabolism.
Objectives
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Conclusion
Investigating the protein expression bottleneck
Common bottlenecks found 
in production of secreted het-
erologous proteins in CHO 
cells, as reported in the litera-
ture1, 2, 3, 4, 5, 6, 7.
We provide evidence that EPO production up to 5 pg/cell/day is not limited by metabolism (i.e. 
glycolysis and associated energy metabolites) or bottlenecks in gene dosage, transcription and 
post-translational processing of EPO. Furthermore, we demonstrate that the amino acid catabo-
lism can adapt to dierent amino acid demand imposed by heterologous protein production 
within 9 generations during prolonged chemostat cultivation. 
Metabolic impact of EPO production
The panel consist of 7 EPO-producing CHO-K1 
clones spanning a 25-fold productivity range. 
Missing gene expression data
Log fold-change
-0.570.65 0
To identify the protein expression bottleneck, we cultured three clones (C1, C4 and C7) in che-
mostat culture for 31 days and determined EPO gene copy numbers, mRNA levels and secreted 
EPO. The post-transcriptional eciency (ratio of EPO per mRNA) indicated a production bottle-
neck enrooted downstream of transcription in clone 1 and 4 relative to clone 7. 
To identify dierentially expressed genes functionally related to secretory protein processing 
across the EPO producers we performed a global gene expression analysis comparing the high-
est and lowest EPO producers (C7 and C1) during phase II (data not shown). The dierential gene 
expression analysis identied no enrichment in the gene expression landscape of genes related 
to protein translocation, protein folding, protein glycosylation or vesicular transport, indicating 
that neither of these processes were limiting protein productivity.
To investigate the impact of EPO production on metabolism, we reconstructed of glycolysis, TCA and 
amino acid catabolism in CHO cells (see link below) and integrated dierential gene expression data 
from phase II of chemostat culture. The data integration revealed decreased transcription level of 
genes responsible for degradation of the amino acids most frequently found in EPO. Thus, indicating 
possible regulatory adaptation of gene expression towards decreased amino acid catabolism specif-
ic for the most abundant amino acids in EPO, in the high producer relative to the low producer.
To discover bottlenecks in glucose metabolism, we quantied intracellular metabolites of glycolysis 
(data not shown) and associated energy metabolites across the EPO producing clones in mid-expo-
nential phase in batch culture. The dierences in concentration showed no correlation to specic 
EPO productivity suggesting EPO production is not limited by energy supply. 
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